Press & news

FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

2023

31 May, 2023 FluoGuide A/S publishes interim report for the period January – March 2023 News English Regulatory Listing Regulation Report Interim Q1 IR
Copenhagen, Denmark, 31 May 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results...
24 May, 2023 FluoGuide provides update on strong clinical trial progress News Corporate Information Other Corporate Information English Regulatory MAR IR
FluoGuide A/S (“FluoGuide” or the “Company”), a Danish biotech company that pioneers precision cancer surgery...
21 March, 2023 FluoGuide awarded prestigious grant together with two academic partners News Corporate Information Other Corporate Information English Regulatory MAR IR
FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that Innovation Fund Denmark (Innovationsfonden)...
21 March, 2023 Minutes from Annual General Meeting in FluoGuide A/S News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR
Copenhagen, Denmark, 21 March 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) held its annual general...
6 March, 2023 Notice of Annual General Meeting in FluoGuide A/S News Corporate Information General meeting Notice English Regulatory Listing Regulation IR
The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64 38 (the...
28 February, 2023 FluoGuide A/S publishes Year-end and annual report for the fiscal year 2022 News English Regulatory Listing Regulation Report Annual IR
27 February, 2023 FluoGuide updates on recruitment in phase IIb aggressive brain cancer trial with FG001 News Corporate Information Other Corporate Information English IR
FluoGuide A/S (“FluoGuide” or the “Company”) provides an update on the clinical timelines for the ongoing clinical...
2 February, 2023 FluoGuide appoints Ole Larsen as CFO News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR
FluoGuide A/S (“FluoGuide” or the “Company”) has appointed Ole Larsen as Chief Financial Officer (“CFO”)...
25 January, 2023 CFO acquired shares in FluoGuide News Corporate Information Other Corporate Information English IR
FluoGuide A/S (“FluoGuide” or the “Company”) announce that the CFO of FluoGuide, Henrik Hang, has acquired...
Next

Calendar &
upcoming reports

30 May 2023

Sedermeradagen

30-31 May 2023

ABGSC Life Science Summit

31 May 2023

Interim report Q1, 2023

1 June 2023

Redeye Growth Day

30 August 2023

Interim report Q2, 2023

14 September 2023

Pareto Securities

29 November 2023

Interim report Q3, 2023

28 February 2024

Year end report 2023

Show all posts

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all